Baseline characteristics of participants in the Physicians' Health Study: a randomized trial of aspirin and beta-carotene in U.S. physicians
- PMID: 1931143
Baseline characteristics of participants in the Physicians' Health Study: a randomized trial of aspirin and beta-carotene in U.S. physicians
Abstract
The Physicians' Health Study is a randomized, double-blind, placebo-controlled trial of primary prevention designed to assess the effects of low-dose aspirin on cardiovascular disease and of beta-carotene on risks of cancer. A total of 22,071 U.S. male physicians 40 to 84 years of age were randomized to one of four treatment groups: active aspirin and active beta-carotene, active aspirin and beta-carotene placebo, aspirin placebo and active beta-carotene, or both placebos. Whereas the beta-carotene component of the trial is ongoing, the blinded aspirin component was terminated early primarily because of a statistically extreme benefit of aspirin on first myocardial infarction. We obtained data relating to a large number of variables, including demographics, personal medical history, family history, health habits, and diet before randomization and compared them among the four treatment groups. As expected in a randomized trial of this sample size, the distribution of baseline characteristics was virtually identical among the treatment groups. This comparison indicates certainly no confounding by the baseline variables that were collected and suggests that other unmeasured or unknown potential confounders are also likely to be distributed evenly between the treatment groups. Thus, any observed differences in outcome between these groups likely result from the effects of the treatments themselves.
Similar articles
-
Biochemical markers of compliance in the Physicians' Health Study.Am J Prev Med. 1990 Sep-Oct;6(5):290-4. Am J Prev Med. 1990. PMID: 2268456 Clinical Trial.
-
Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis.Cancer Res. 1999 Mar 15;59(6):1225-30. Cancer Res. 1999. PMID: 10096552
-
Beta-carotene supplementation for patients with low baseline levels and decreased risks of total and prostate carcinoma.Cancer. 1999 Nov 1;86(9):1783-92. Cancer. 1999. PMID: 10547552 Clinical Trial.
-
The role of beta-carotene in the prevention of cardiovascular disease.Ann N Y Acad Sci. 1993 Dec 31;691:148-55. doi: 10.1111/j.1749-6632.1993.tb26166.x. Ann N Y Acad Sci. 1993. PMID: 8129284 Review. No abstract available.
-
Contributions of observational evidence and clinical trials in cancer prevention.Cancer. 1994 Nov 1;74(9 Suppl):2625-9. doi: 10.1002/1097-0142(19941101)74:9+<2625::aid-cncr2820741807>3.0.co;2-o. Cancer. 1994. PMID: 7954276 Review.
Cited by
-
Metabolic abnormalities and risk for colorectal cancer in the physicians' health study.Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2391-7. doi: 10.1158/1055-9965.EPI-06-0391. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 17164361 Free PMC article.
-
Alcohol consumption and functional outcome after stroke in men.Stroke. 2010 Jan;41(1):141-6. doi: 10.1161/STROKEAHA.109.562173. Epub 2009 Nov 12. Stroke. 2010. PMID: 19910548 Free PMC article. Clinical Trial.
-
Aspirin use and risk of type 2 diabetes in apparently healthy men.Am J Med. 2009 Apr;122(4):374-9. doi: 10.1016/j.amjmed.2008.09.044. Epub 2009 Feb 21. Am J Med. 2009. PMID: 19233341 Free PMC article. Clinical Trial.
-
Association of Prediagnostic Blood Metabolomics with Prostate Cancer Defined by ERG or PTEN Molecular Subtypes.Cancer Epidemiol Biomarkers Prev. 2021 May;30(5):1000-1008. doi: 10.1158/1055-9965.EPI-20-1363. Epub 2021 Feb 24. Cancer Epidemiol Biomarkers Prev. 2021. PMID: 33627383 Free PMC article.
-
Physical activity and functional outcomes from cerebral vascular events in men.Stroke. 2011 Dec;42(12):3352-6. doi: 10.1161/STROKEAHA.111.619544. Epub 2011 Sep 22. Stroke. 2011. PMID: 21940956 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical
Research Materials